Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
May 2011
Features
Roles of EGFR and KRAS Mutations in the Treatment of Patients With Non–Small-Cell Lung Cancer
Determining the mutation status of two genes, EGFR and KRAS, may enable health care professionals to identify which patients with non–small-cell lung cancer are likely to benefit from anti-epidermal growth factor receptor–tyrosine kinase inhibitor therapy rather than from chemotherapy.
Corey J. Langer, MD
The 340B Discount Drug Program at Ozarks Medical Center
An Economic Stimulus Plan for Missouri
Although many safety-net hospitals are facing reductions in Medicaid assistance, one facility has begun to transform its pharmacy program into a revenue producer based on expanded 340B access.
Stephen Barlas
Treatment Options for Obesity and Potential Therapies on the Horizon
Of the many drugs that have been submitted to the FDA for treating obesity, only two are approved, and some that had been approved earlier have been removed from the market. The authors discuss the benefits and risks of several agents while noting the difficulty in obtaining approval for a safe weight-loss medication.
Carol A. Motycka, PharmD; Erin St. Onge, PharmD; and Shannon A. Miller, PharmD
Pharmaceutical Approval Update
Belimumab (Benlysta) for lupus and ipilimumab (Yervoy) for melanoma
Marvin M. Goldenberg, PhD, RPh, MS
Meeting Highlights
American Academy of Dermatology
High-dose isotretinoin (Accutane) for nodulocystic acne, briakinumab for psoriasis, biologics for psoriasis comorbidities, and therapies for nail fungal infections
Peter Sonnenreich, MA
Meeting Highlights
11th European Congress on Osteoporosis and Osteoarthritis and International Liver Congress 2011 (46th European Association for the Study of the Liver)
Strontium ranelate (Protelos), zoledronic acid (Zometa), and denosumab (Prolia)
for bone health; boceprevir (Victrelis) and telaprevir for hepatitis C virus infection
Walter Alexander
Departments
Medication Errors
Potassium Chloride Injection Still Poses Threats to Patients
Although potassium chloride is no longer stocked in patient-care units, this high alert drug can still pose a serious threat to patients.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Severe Drug Shortages Impose Heavy Costs on Hospital Pharmacies
Senate Bill Might Help … or Not
A Senate bill, if passed, could help to alleviate the epidemic of widespread severe drug shortages, which cost hospital pharmacies at least $200 million annually.
Stephen Barlas
New Drugs/Drug News/New Medical Devices
FDA approvals, drug indications, and updates
Drug Forecast
Naltrexone SR/Bupropion SR (Contrave)
A New Approach to Weight Loss in Obese Adults
Naltrexone SR/bupropion SR (Contrave) for weight loss
Tehane Ornellas, PharmD Candidate; and Benjamin Chavez, PharmD, BCPP
